Ahn-Gook Pharmaceutical Co., Ltd.

KOSDAQ:A001540 Stock Report

Market Cap: ₩75.4b

Ahn-Gook Pharmaceutical Past Earnings Performance

Past criteria checks 4/6

Ahn-Gook Pharmaceutical has been growing earnings at an average annual rate of 37.7%, while the Pharmaceuticals industry saw earnings growing at 7.3% annually. Revenues have been growing at an average rate of 12.3% per year. Ahn-Gook Pharmaceutical's return on equity is 8.4%, and it has net margins of 5.4%.

Key information

37.7%

Earnings growth rate

37.8%

EPS growth rate

Pharmaceuticals Industry Growth11.3%
Revenue growth rate12.3%
Return on equity8.4%
Net Margin5.4%
Last Earnings Update30 Sep 2024

Recent past performance updates

Statutory Earnings May Not Be The Best Way To Understand Ahn-Gook Pharmaceutical's (KOSDAQ:001540) True Position

Aug 26
Statutory Earnings May Not Be The Best Way To Understand Ahn-Gook Pharmaceutical's (KOSDAQ:001540) True Position

Recent updates

Statutory Earnings May Not Be The Best Way To Understand Ahn-Gook Pharmaceutical's (KOSDAQ:001540) True Position

Aug 26
Statutory Earnings May Not Be The Best Way To Understand Ahn-Gook Pharmaceutical's (KOSDAQ:001540) True Position

Pinning Down Ahn-Gook Pharmaceutical Co., Ltd.'s (KOSDAQ:001540) P/E Is Difficult Right Now

Aug 13
Pinning Down Ahn-Gook Pharmaceutical Co., Ltd.'s (KOSDAQ:001540) P/E Is Difficult Right Now

Are Dividend Investors Making A Mistake With Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540)?

Apr 02
Are Dividend Investors Making A Mistake With Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540)?

Ahn-Gook Pharmaceutical (KOSDAQ:001540) Shareholders Booked A 29% Gain In The Last Year

Mar 07
Ahn-Gook Pharmaceutical (KOSDAQ:001540) Shareholders Booked A 29% Gain In The Last Year

Is Ahn-Gook Pharmaceutical (KOSDAQ:001540) Using Too Much Debt?

Feb 14
Is Ahn-Gook Pharmaceutical (KOSDAQ:001540) Using Too Much Debt?

Do Insiders Own Lots Of Shares In Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540)?

Jan 19
Do Insiders Own Lots Of Shares In Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540)?

Dividend Investors: Don't Be Too Quick To Buy Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540) For Its Upcoming Dividend

Dec 24
Dividend Investors: Don't Be Too Quick To Buy Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540) For Its Upcoming Dividend

A Look At The Fair Value Of Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540)

Dec 10
A Look At The Fair Value Of Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540)

Key Things To Consider Before Buying Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540) For Its Dividend

Nov 18
Key Things To Consider Before Buying Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540) For Its Dividend

Revenue & Expenses Breakdown

How Ahn-Gook Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A001540 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24264,63614,281138,95112,256
30 Jun 24252,48015,349132,54212,334
31 Mar 24244,2236,406127,18912,124
31 Dec 23233,6761,290122,10112,255
30 Sep 23226,1864,581118,67513,045
30 Jun 23224,2197,801113,49813,290
31 Mar 23213,4148,298106,30513,384
31 Dec 22205,3896,875102,47712,957
30 Sep 22195,7409,471100,57912,613
30 Jun 22182,7607,00594,84213,243
31 Mar 22175,1634,07791,38415,523
31 Dec 21163,5343,93983,32917,328
30 Sep 21149,1371,39172,66217,768
30 Jun 21143,73424270,04617,789
31 Mar 21141,126-2,50565,99317,405
31 Dec 20143,364-1,31566,04616,993
30 Sep 20156,318-1,00368,85628,013
30 Jun 20160,05921569,72923,942
31 Mar 20158,8703,33972,86216,351
31 Dec 19155,8522,53674,16115,583
30 Sep 19167,3927,41675,40726
30 Jun 19173,0648,52477,36041
31 Mar 19179,16612,86277,0413,058
31 Dec 18185,74613,22081,14177
30 Sep 18177,6637,11184,41071
30 Jun 18177,6018,64182,71071
31 Mar 18179,5568,20983,90866
31 Dec 17183,6008,15980,68184
30 Sep 17182,0329,83973,53184
30 Jun 17179,0485,88470,90485
31 Mar 17176,1782,70066,954109
31 Dec 16174,0021,71565,440104
30 Sep 16183,923-18565,040298
30 Jun 16188,1943,02565,797281
31 Mar 16195,8717,92667,732240
31 Dec 15197,7369,36466,948213
30 Sep 15185,5694,36064,593452
30 Jun 15181,9733,17164,641452
31 Mar 15173,7841,12361,423452
31 Dec 14167,936-78458,404452
30 Sep 14161,7037,56255,735591
30 Jun 14154,3806,77554,374591
31 Mar 14152,9454,30854,535591

Quality Earnings: A001540 has a high level of non-cash earnings.

Growing Profit Margin: A001540's current net profit margins (5.4%) are higher than last year (2%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A001540's earnings have grown significantly by 37.7% per year over the past 5 years.

Accelerating Growth: A001540's earnings growth over the past year (211.7%) exceeds its 5-year average (37.7% per year).

Earnings vs Industry: A001540 earnings growth over the past year (211.7%) exceeded the Pharmaceuticals industry 25.3%.

Return on Equity

High ROE: A001540's Return on Equity (8.4%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/04 07:37
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ahn-Gook Pharmaceutical Co., Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Min-young LeeKorea Investment & Securities Co., Ltd.